ASX Announcements

Nov 2019
Nov 12th, 2019
Notice of initial substantial holder

Oct 2019
Oct 31st, 2019
DEP® gemcitabine outperforms Gemzar® in human pancreatic cancer model
Oct 30th, 2019
Quarterly Cashflow Report
Oct 23rd, 2019
Ceasing to be a substantial holder
Oct 23rd, 2019
Change in substantial holding
Oct 18th, 2019
Notice of Annual General Meeting/Proxy Form
Oct 17th, 2019
Appendix 3B
Oct 8th, 2019
Starpharma to present at US Drug Delivery Conference
Oct 1st, 2019
Change in Director's Interest Notice - J Fairley
Oct 1st, 2019
Appendix 3B

Sep 2019
Sep 26th, 2019
FDA Authorisation of First-in-Human Clinical Trial with AstraZeneca’s DEP® product AZD0466
Sep 24th, 2019
AGM Date Notification
Sep 12th, 2019
DEP® irinotecan synergistic with Lynparza® in refractory human colon cancer model
Sep 9th, 2019
Change in substantial holding
Sep 3rd, 2019
VivaGel® BV regulatory approvals continue in Asia

Aug 2019
Aug 29th, 2019
Positive results with Targeted DEP® using antibody fragment in human ovarian cancer model
Aug 28th, 2019
Starpharma annual report and full year financial results
Aug 28th, 2019
Appendix 4G – Corporate Governance Statement
Aug 28th, 2019
Promising efficacy signals observed in ongoing DEP® trials, including DEP® cabazitaxel escalation phase
Aug 15th, 2019
First Asian Regulatory Approvals Received for VivaGel® BV
Aug 8th, 2019
Starpharma commences phase 1/2 DEP® irinotecan trial

Jul 2019
Jul 29th, 2019
Appendix 3B
Jul 16th, 2019
Quarterly Cashflow Report
Jul 1st, 2019
Shareholder Update July 2019

Jun 2019
Jun 27th, 2019
VivaGel® BV launched in Europe
Jun 20th, 2019
Starpharma presents at Macquarie Emerging Leaders Forum
Jun 12th, 2019
US patent granted for DEP Bcl2/xL inhibitor conjugates
Jun 4th, 2019
Okamoto launches VivaGel® condom in Japan
Jun 3rd, 2019
Starpharma signs second oncology agreement with AstraZeneca

May 2019
May 29th, 2019
Starpharma presents at UBS Healthcare Conference
May 24th, 2019
DEP irinotecan combination outperforms in refractory human colon cancer model
May 23rd, 2019
Regulatory progress for VivaGel BV in the US
May 7th, 2019
Starpharma to present at US Drug Delivery Conference
May 1st, 2019
Starpharma presents at Macquarie Australia Conference
May 1st, 2019
Notice of Ceasing to be Substantial Holder

Apr 2019
Apr 29th, 2019
Quarterly Cashflow Report
Apr 16th, 2019
First VivaGel BV launch globally in Australia by Aspen
Apr 11th, 2019
Starpharma meets with US FDA to discuss VivaGel® BV
Apr 3rd, 2019
Starpharma Investor Presentation to Goldman Sachs Conference

Mar 2019
Mar 19th, 2019
Appendix 3B
Mar 18th, 2019
Shareholder Update March 2019
Mar 12th, 2019
Starpharma receives $4.0M R&D tax incentive refund

Feb 2019
Feb 27th, 2019
Interim Report and Half-Yearly Financial Results
Feb 8th, 2019
Appendix 3B

Jan 2019
Jan 30th, 2019
Quarterly Cashflow Report
Jan 17th, 2019
Shareholder Update January 2019
Jan 14th, 2019
Notice of initial substantial holder
Jan 7th, 2019
SPL - Response to ASX Aware Letter
Jan 2nd, 2019
VivaGel® condom receives final regulatory approval in Japan